Welcome to our dedicated page for Solana news (Ticker: HSDT), a resource for investors and traders seeking the latest updates and insights on Solana stock.
Solana Company reports developments as a Nasdaq-listed company with a digital asset treasury dedicated to acquiring and holding Solana tokens (SOL) and a legacy neurotechnology medical-device business. News commonly covers SOL accumulation, staking rewards, NAV-per-share capital strategy, ATM and registered-direct equity financing, share repurchases, and financial results shaped by digital-asset fair value changes.
Company updates also describe institutional Solana infrastructure initiatives in Asia-Pacific, including validator and staking infrastructure, qualified-custody borrowing against natively staked SOL, and ecosystem partnerships with organizations such as Jito Foundation, Anchorage Digital, and Kamino.
Helius Medical Technologies (HSDT) announced the approval of an equity award under its 2021 Inducement Plan, as a material inducement for a new employee effective September 13, 2022. The award comprises an option to purchase 10,000 shares at an exercise price of $0.54 per share, matching the closing price on the grant date. The option vests over four years, with 25% vesting annually. Helius is focused on neurological wellness and has developed the Portable Neuromodulation Stimulator (PoNS), aimed at treating gait deficits from conditions like multiple sclerosis.
Helius Medical Technologies, Inc. (Nasdaq:HSDT) announced that its executives will present at two healthcare conferences this September. The first is the H.C. Wainwright 24th Annual Global Investment Conference (September 12-14, 2022), available on demand. The second is the Ladenburg Thalmann Healthcare Conference in New York City on September 29, 2022, at 10:00 AM ET. Helius focuses on neurological wellness and offers the Portable Neuromodulation Stimulator (PoNS), a non-surgical device aimed at improving balance and gait for patients with multiple sclerosis and traumatic brain injury.
Helius Medical Technologies, Inc. (Nasdaq:HSDT) reported Q2 2022 financial results with revenues increasing by 68% to $119K, primarily from PoNS Therapy sales for MS patients. The company initiated U.S. commercial sales and launched a Patient Therapy Access Program to improve accessibility. Operating expenses decreased to $3.5M, leading to a reduced net loss of $3.8M compared to $6.0M in Q2 2021. Cash reserves total $19.7M post-recent financing, expected to fund operations through 2023. The company anticipates modest revenue growth for Q3, driven by continued sales coverage and patient pairing efforts.
Helius Medical Technologies (NASDAQ: HSDT) will release its Q2 2022 financial results on August 15, 2022, after market close. CEO Dane C. Andreeff and CFO Jeffrey S. Mathiesen will host a conference call at 4:30 p.m. ET to discuss results and provide updates on the U.S. commercialization of its product, the Portable Neuromodulation Stimulator (PoNS). This innovative device aims to assist individuals with gait deficits due to multiple sclerosis. The conference call requires prior registration for dial-in details.
Helius Medical Technologies (Nasdaq: HSDT) announced a public offering of 24 million shares of Class A common stock and warrants for 36 million shares, priced at $0.75 each. The offering is expected to close around August 9, 2022, aiming to raise approximately $18 million in gross proceeds, intended for funding operations and working capital. Roth Capital Partners and Maxim Group are the lead and co-placement agents, respectively. The offering is registered under effective SEC statements, ensuring compliance with securities laws.
Helius Medical Technologies (Nasdaq:HSDT) has launched a new online training module for physical therapists aimed at treating gait deficits in multiple sclerosis (MS) patients. This shift from in-person training to an online format allows therapists to complete the training in under three hours, significantly increasing accessibility. Currently, 55 therapists in the U.S. and 20 in Canada are queued for training. Helius aims to standardize training and enhance the delivery of PoNS Therapy, intended for individuals with mild to moderate MS symptoms.
Helius Medical Technologies (Nasdaq: HSDT) presented a poster on the effectiveness of its Portable Neuromodulation Stimulator (PoNS) Therapy at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting. The study demonstrated significant gait improvement in patients with multiple sclerosis (MS) after two weeks of therapy. The poster was nominated for the prestigious Labe C. Scheinberg Award, highlighting its impact in advancing MS care. Helius plans to gather further evidence through its Therapeutic Experience Program, reinforcing its commitment to improving neurological wellness.
Helius Medical Technologies (Nasdaq:HSDT) launched a Patient Therapy Access Program (PTAP) to improve access to its Portable Neuromodulation Stimulator (PoNS) Therapy for patients with multiple sclerosis (MS). This initiative offers eligible patients reduced pricing for PoNS, which is prescribed for gait deficits due to mild-to-moderate MS symptoms. The program aims to drive adoption of PoNS Therapy and supports data collection for future clinical evidence. PTAP will run until December 31, 2022, enhancing access for first-time users of the therapy.
Helius Medical Technologies (Nasdaq: HSDT) announced a poster presentation at the Consortium for Multiple Sclerosis Centers (CMSC) Annual Meeting from June 1-4, 2022. The highlighted abstract showcases real-world data indicating that translingual neurostimulation can effectively improve gait in multiple sclerosis patients. Chief Medical Officer Antonella Favit-Van Pelt emphasized the benefits of neuromodulation in enhancing walking stability and promoting neuroplasticity. The presentation is scheduled for June 2 at 5:00 p.m. ET, with Helius representatives available to discuss the Portable Neuromodulation Stimulator (PoNS) device at Booth #804.
Helius Medical Technologies (HSDT) announced that its independent directors have approved the issuance of equity awards as part of its 2021 Inducement Plan, effective May 23, 2022. Four new employees, not previously associated with Helius, received options to purchase a total of 21,000 shares at an exercise price of $1.40 each, which reflects the closing stock price on the date of the grant. These options will vest over four years, providing Helius with a strategic advantage in attracting talent while adhering to Nasdaq regulations.